Published in Drug Saf on January 01, 2009
Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology (2008) 5.45
Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study. Gastroenterology (2015) 2.43
Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology (2010) 2.30
Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop. Hepatology (2010) 2.28
Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury. Gastroenterology (2011) 2.25
Persistent Liver Biochemistry Abnormalities Are More Common in Older Patients and those With Cholestatic Drug Induced Liver Injury. Am J Gastroenterol (2015) 2.08
Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology (2011) 2.01
Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network. Hepatology (2014) 1.83
Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. Hepatology (2013) 1.81
Serum proteomic profiling in patients with drug-induced liver injury. Aliment Pharmacol Ther (2012) 1.55
Important elements for the diagnosis of drug-induced liver injury. Clin Gastroenterol Hepatol (2010) 1.50
Relationship between characteristics of medications and drug-induced liver disease phenotype and outcome. Clin Gastroenterol Hepatol (2013) 1.46
RUCAM in Drug and Herb Induced Liver Injury: The Update. Int J Mol Sci (2015) 1.45
Under-reporting and Poor Adherence to Monitoring Guidelines for Severe Cases of Isoniazid Hepatotoxicity. Clin Gastroenterol Hepatol (2015) 1.43
Catechins in dietary supplements and hepatotoxicity. Dig Dis Sci (2013) 1.31
Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset. Gastroenterology (2014) 1.31
Population-representative incidence of drug-induced acute liver failure based on an analysis of an integrated health care system. Gastroenterology (2015) 1.30
Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives. Gastroenterology (2013) 1.24
Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs. Pharmacogenet Genomics (2012) 1.21
Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network. Hepatology (2014) 1.19
A collaborative approach to developing an electronic health record phenotyping algorithm for drug-induced liver injury. J Am Med Inform Assoc (2013) 1.14
Hepatotoxicity due to hydroxycut: a case series. Am J Gastroenterol (2010) 1.14
Characteristics of idiosyncratic drug-induced liver injury in children: results from the DILIN prospective study. J Pediatr Gastroenterol Nutr (2011) 1.12
Polymerase γ gene POLG determines the risk of sodium valproate-induced liver toxicity. Hepatology (2010) 1.08
Drug-induced liver injury: present and future. Clin Mol Hepatol (2012) 1.06
Clinical and histopathologic features of fluoroquinolone-induced liver injury. Clin Gastroenterol Hepatol (2011) 1.05
Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database. Drug Saf (2015) 1.02
Reliability of causality assessment for drug, herbal and dietary supplement hepatotoxicity in the Drug-Induced Liver Injury Network (DILIN). Liver Int (2014) 1.02
Drug-drug interactions with oral anti-HCV agents and idiosyncratic hepatotoxicity in the liver transplant setting. J Hepatol (2013) 1.01
Drug-induced liver injury in hospitalized patients with notably elevated alanine aminotransferase. World J Gastroenterol (2012) 0.97
Drug- and Herb-Induced Liver Injury in Clinical and Translational Hepatology: Causality Assessment Methods, Quo Vadis? J Clin Transl Hepatol (2013) 0.96
Duloxetine hepatotoxicity: a case-series from the drug-induced liver injury network. Aliment Pharmacol Ther (2010) 0.96
Causality assessment for suspected DILI during clinical phases of drug development. Drug Saf (2014) 0.91
Update on Advances in Research on Idiosyncratic Drug-Induced Liver Injury. Allergy Asthma Immunol Res (2015) 0.91
Statin-induced liver injury in an area endemic for hepatitis B virus infection: risk factors and outcome analysis. Br J Clin Pharmacol (2016) 0.90
Clinical and histologic features of azithromycin-induced liver injury. Clin Gastroenterol Hepatol (2014) 0.89
Sensitivity to hepatotoxicity due to epigallocatechin gallate is affected by genetic background in diversity outbred mice. Food Chem Toxicol (2014) 0.88
Comparative analysis of portal hepatic infiltrating leucocytes in acute drug-induced liver injury, idiopathic autoimmune and viral hepatitis. Clin Exp Immunol (2015) 0.88
Clinical and histological features of idiosyncratic acute liver injury caused by temozolomide. Dig Dis Sci (2012) 0.88
Herbal hepatotoxicity: challenges and pitfalls of causality assessment methods. World J Gastroenterol (2013) 0.87
Acute liver injury due to flavocoxid (Limbrel), a medical food for osteoarthritis: a case series. Ann Intern Med (2012) 0.87
Febuxostat-induced acute liver injury. Hepatology (2016) 0.87
Presentation and outcomes with clinically apparent interferon beta hepatotoxicity. Dig Dis Sci (2013) 0.86
Japan PGx Data Science Consortium Database: SNPs and HLA genotype data from 2994 Japanese healthy individuals for pharmacogenomics studies. J Hum Genet (2015) 0.85
Case Characterization, Clinical Features and Risk Factors in Drug-Induced Liver Injury. Int J Mol Sci (2016) 0.85
A Text Searching Tool to Identify Patients with Idiosyncratic Drug-Induced Liver Injury. Dig Dis Sci (2015) 0.85
Clinical Features and Outcomes of Complementary and Alternative Medicine Induced Acute Liver Failure and Injury. Am J Gastroenterol (2016) 0.85
Detective work in drug-induced liver injury: sometimes it is all about interviewing the right witness. Clin Gastroenterol Hepatol (2010) 0.84
Features of Autoimmune Hepatitis in Patients With Drug-induced Liver Injury. Clin Gastroenterol Hepatol (2016) 0.84
Profiles of serum cytokines in acute drug-induced liver injury and their prognostic significance. PLoS One (2013) 0.84
Assessing liver injury associated with antimycotics: Concise literature review and clues from data mining of the FAERS database. World J Hepatol (2014) 0.82
Prevalence of genetic variants of keratins 8 and 18 in patients with drug-induced liver injury. BMC Med (2015) 0.82
Drug-Induced Liver Injury Network Causality Assessment: Criteria and Experience in the United States. Int J Mol Sci (2016) 0.81
Scientific and Regulatory Perspectives in Herbal and Dietary Supplement Associated Hepatotoxicity in the United States. Int J Mol Sci (2016) 0.81
Evaluation considerations for EHR-based phenotyping algorithms: A case study for drug-induced liver injury. AMIA Jt Summits Transl Sci Proc (2013) 0.81
The Role of Adverse Event Reporting in the FDA Response to a Multistate Outbreak of Liver Disease Associated with a Dietary Supplement. Public Health Rep (2015) 0.81
Data-driven identification of structural alerts for mitigating the risk of drug-induced human liver injuries. J Cheminform (2015) 0.81
Genetic basis of susceptibility to drug-induced liver injury: what have we learned and where do we go from here? Pharmacogenomics (2012) 0.81
Amoxicillin-Clavulanate-Induced Liver Injury. Dig Dis Sci (2016) 0.80
Drug Induced Liver Injury: Review with a Focus on Genetic Factors, Tissue Diagnosis, and Treatment Options. J Clin Transl Hepatol (2015) 0.80
Khat (Catha Edulis) as a possible cause of autoimmune hepatitis. World J Hepatol (2014) 0.80
Identification and Characterization of Cefazolin-Induced Liver Injury. Clin Gastroenterol Hepatol (2014) 0.79
Frequency, clinical presentation, and outcomes of drug-induced liver injury after liver transplantation. Liver Transpl (2012) 0.78
Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-wide Association Study. Gastroenterology (2016) 0.77
Suspected Liver Injury and the Dilemma of Causality. Dig Dis Sci (2017) 0.76
Statins and liver injury. Gastroenterol Hepatol (N Y) (2013) 0.76
Herbal and dietary supplement-induced liver injury. Gastroenterol Hepatol (N Y) (2011) 0.76
Drug-induced Liver Injury. US Gastroenterol Hepatol Rev (2010) 0.76
Liver injury from nonsteroidal anti-inflammatory drugs in the United States. Liver Int (2015) 0.76
Acute liver injury associated with a newer formulation of the herbal weight loss supplement Hydroxycut. BMJ Case Rep (2015) 0.76
The Need for Biomarkers in Diagnosis and Prognosis of Drug-Induced Liver Disease: Does Metabolomics Have Any Role? Biomed Res Int (2015) 0.76
Minocycline hepatotoxicity: Clinical characterization and identification of HLA-B∗35:02 as a risk factor. J Hepatol (2017) 0.76
New approaches for predicting T cell-mediated drug reactions: A role for inducible and potentially preventable autoimmunity. J Allergy Clin Immunol (2015) 0.75
Clinical Presentations and Outcomes of Bile Duct Loss caused by Drugs and Herbal and Dietary Supplements. Hepatology (2016) 0.75
Risk of Liver Injury Associated with Green Tea Extract in SLIMQUICK(®) Weight Loss Products: Results from the DILIN Prospective Study. Drug Saf (2016) 0.75
Hepatotoxicity Secondary to Chemotherapy. J Clin Transl Hepatol (2014) 0.75
Genetic Variations in TXNRD1 as Potential Predictors of Drug-Induced Liver Injury. Allergy Asthma Immunol Res (2011) 0.75
Comparison of Liver Biopsy Findings with the Digestive Disease Week Japan 2004 Scale for Diagnosis of Drug-Induced Liver Injury. Mediators Inflamm (2015) 0.75
Association study of UGT1A9 promoter polymorphisms with DILI based on systematically regional variation screen in Chinese population. Pharmacogenomics J (2014) 0.75
Severe Acute Hepatocellular Injury Attributed to OxyELITE Pro: A Case Series. Dig Dis Sci (2016) 0.75
Chinese herbal medicine Tangshen Formula treatment of patients with type 2 diabetic kidney disease with macroalbuminuria: study protocol for a randomized controlled trial. Trials (2016) 0.75
Drug-induced liver injury: Do we know everything? World J Hepatol (2017) 0.75
Associations of gender and a proxy of female menopausal status with histological features of drug-induced liver injury. Liver Int (2017) 0.75
Identification and Characterization of Fenofibrate-Induced Liver Injury. Dig Dis Sci (2017) 0.75
Idiosyncratic Drug Induced Liver Injury in African-Americans Is Associated With Greater Morbidity and Mortality Compared to Caucasians. Am J Gastroenterol (2017) 0.75
Death and Liver Transplantation within Two Years of Onset of Drug-Induced Liver Injury. Hepatology (2017) 0.75
Development of a modified lymphocyte transformation test for diagnosing drug-induced liver injury associated with an adaptive immune response. J Immunotoxicol (2017) 0.75
Preliminary Results of a Novel Algorithmic Method Aiming to Support Initial Causality Assessment of Routine Pharmacovigilance Case Reports for Medication-Induced Liver Injury: The PV-RUCAM. Drug Saf (2017) 0.75
The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care (1992) 144.02
Chronic hepatitis B. Hepatology (2007) 13.75
Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med (2002) 11.38
The PedsQL 4.0 as a pediatric population health measure: feasibility, reliability, and validity. Ambul Pediatr (2003) 8.61
Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol (1993) 7.63
Drug-related hepatotoxicity. N Engl J Med (2006) 7.49
Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol (1990) 5.66
Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology (2008) 5.45
Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology (2002) 3.64
Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology (2005) 3.52
Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions. Arch Intern Med (2005) 2.73
Drinking from the fire hose--statistical issues in genomewide association studies. N Engl J Med (2007) 2.49
American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology (2006) 2.39
Outcome and prognostic markers in severe drug-induced liver disease. Hepatology (2005) 2.36
Drug-induced liver injury: summary of a single topic clinical research conference. Hepatology (2006) 2.24
Acetaminophen hepatotoxicity: the first 35 years. J Toxicol Clin Toxicol (2002) 2.21
The prevalence and predictors of elevated serum aminotransferase activity in the United States in 1999-2002. Am J Gastroenterol (2006) 2.13
Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow-up in a hepatotoxicity registry. Hepatology (2006) 2.12
Severe hepatotoxicity associated with the dietary supplement LipoKinetix. Ann Intern Med (2002) 2.06
Prospective surveillance of acute serious liver disease unrelated to infectious, obstructive, or metabolic diseases: epidemiological and clinical features, and exposure to drugs. J Hepatol (2002) 1.74
The causes of obvious jaundice in South West Wales: perceptions versus reality. Gut (2001) 1.70
Drug-induced liver injury network (DILIN). Hepatology (2004) 1.64
Prevalence and interaction of hepatitis B and latent tuberculosis in Vietnamese immigrants to the United States. Am J Gastroenterol (2002) 1.57
Reliability of the Roussel Uclaf Causality Assessment Method for assessing causality in drug-induced liver injury. Hepatology (2008) 1.53
Recognizing drug-induced liver injury: current problems, possible solutions. Toxicol Pathol (2005) 1.45
The natural history of histologically proved drug induced liver disease. Gut (1999) 1.43
Drug-induced liver injury in a Swedish University hospital out-patient hepatology clinic. Aliment Pharmacol Ther (2006) 1.43
Primary sclerosing cholangitis: summary of a workshop. Hepatology (2006) 1.38
Chronic active hepatitis and severe hepatic necrosis associated with nitrofurantoin. Ann Intern Med (1980) 1.36
Causality assessment of drug-induced hepatotoxicity: promises and pitfalls. Clin Liver Dis (2007) 1.32
Role of metabolism in drug-induced idiosyncratic hepatotoxicity. Crit Rev Toxicol (2005) 1.24
Safety of disease modifying anti-rheumatic agents in rheumatoid arthritis patients with chronic viral hepatitis. Clin Exp Rheumatol (2000) 1.18
The burden of acute nonfulminant drug-induced hepatitis in a United States tertiary referral center [corrected]. J Clin Gastroenterol (2005) 1.18
Troglitazone-induced liver failure: a case study. Am J Med (2003) 1.15
Methotrexate-associated hepatotoxicity: retrospective analysis of 210 patients with rheumatoid arthritis. Am J Med (1988) 1.10
HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease. Hepatology (2004) 1.09
Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. Drug Saf (2005) 1.07
Hepatotoxicity in drug development: detection, significance and solutions. J Hepatol (1997) 1.06
Causality assessment versus guilt-by-association in drug hepatotoxicity. Hepatology (2001) 1.05
Hepatic findings in long-term clinical trials of ximelagatran. Drug Saf (2005) 1.05
Antiretroviral-associated liver injury. Clin Liver Dis (2003) 0.97
Hepatitis induced by Kava (Piper methysticum rhizoma). J Hepatol (2003) 0.93
The need for a population-based surveillance system for liver disease in the United States. Pharmacoepidemiol Drug Saf (2004) 0.83
Acute liver failure associated with prolonged use of bromfenac leading to liver transplantation. The Acute Liver Failure Study Group. Liver Transpl Surg (1999) 0.83
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med (2010) 13.33
A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab (2009) 11.46
Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med (2008) 9.33
A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet (2013) 6.19
Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology (2008) 6.15
Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology (2008) 5.45
Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology (2009) 4.90
Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology (2004) 4.27
Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation (2003) 4.00
Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. Hepatology (2009) 3.50
Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials (2004) 3.46
Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA (2011) 3.37
Vascular endothelium as a contributor of plasma sphingosine 1-phosphate. Circ Res (2008) 3.36
Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology (2010) 3.35
Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology (2011) 2.97
Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial. Clin Gastroenterol Hepatol (2010) 2.96
Recommendations for the diagnosis and treatment of the acute porphyrias. Ann Intern Med (2005) 2.95
Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology (2009) 2.92
Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology (2010) 2.86
Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. Hepatology (2008) 2.66
Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol (2005) 2.63
Inhibitory effects of microRNA 19b in hepatic stellate cell-mediated fibrogenesis. Hepatology (2012) 2.61
Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology (2010) 2.47
Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. Hepatology (2008) 2.44
Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology (2011) 2.44
Dance and reducing television viewing to prevent weight gain in African-American girls: the Stanford GEMS pilot study. Ethn Dis (2003) 2.41
Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. Nat Rev Drug Discov (2007) 2.32
Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology (2010) 2.30
Initial experience with EUS-guided Tru-cut biopsy of benign liver disease. Gastrointest Endosc (2009) 2.30
Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop. Hepatology (2010) 2.28
Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury. Gastroenterology (2011) 2.25
Intensive care of patients with acute liver failure: recommendations of the U.S. Acute Liver Failure Study Group. Crit Care Med (2007) 2.17
Role of Bach1 and Nrf2 in up-regulation of the heme oxygenase-1 gene by cobalt protoporphyrin. FASEB J (2006) 2.16
An after-school obesity prevention program for African-American girls: the Minnesota GEMS pilot study. Ethn Dis (2003) 2.12
Hepatitis C, porphyria cutanea tarda and liver iron: an update. Liver Int (2012) 2.10
Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial. Hepatology (2006) 2.06
Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C. Hepatology (2008) 2.02
Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology (2011) 2.01
The Fun, Food, and Fitness Project (FFFP): the Baylor GEMS pilot study. Ethn Dis (2003) 2.00
Endoscopic therapy with 2-octyl-cyanoacrylate for the treatment of gastric varices. Dig Dis Sci (2014) 1.99
Hepatotoxicity associated with supplements containing Chinese green tea (Camellia sinensis). Ann Intern Med (2006) 1.95
Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation (2004) 1.94
Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. Hepatology (2005) 1.93
Serum proteomics and biomarker discovery across the spectrum of nonalcoholic fatty liver disease. Hepatology (2010) 1.91
Validity and reliability of activity measures in African-American girls for GEMS. Med Sci Sports Exerc (2003) 1.86
Fulminant hepatitis A virus infection in the United States: Incidence, prognosis, and outcomes. Hepatology (2006) 1.83
Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network. Hepatology (2014) 1.83
Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. Hepatology (2013) 1.81
Weight-related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial. Gastroenterology (2009) 1.80
An assessment of statin safety by hepatologists. Am J Cardiol (2006) 1.78
Nutritional model of steatohepatitis and metabolic syndrome in the Ossabaw miniature swine. Hepatology (2009) 1.78
Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C. Gut (2010) 1.78
Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology (2006) 1.76
Liver transplantation for erythropoietic protoporphyria liver disease. Liver Transpl (2005) 1.76
Unexplained elevations in alanine aminotransferase in individuals with the metabolic syndrome: results from the third National Health and Nutrition Survey (NHANES III). Am J Med Sci (2005) 1.76
Steroid and xenobiotic receptor and vitamin D receptor crosstalk mediates CYP24 expression and drug-induced osteomalacia. J Clin Invest (2006) 1.75
Contemporary clinical research of traditional Chinese medicines for chronic hepatitis B in China: an analytical review. Hepatology (2010) 1.71
DNA polymorphisms and response to treatment in patients with chronic hepatitis C: results from the HALT-C trial. J Hepatol (2008) 1.71
Relationship between hepatitis C and microalbuminuria: results from the NHANES III. Kidney Int (2005) 1.71
Hepatic steatosis in hepatitis C: comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trial. Clin Gastroenterol Hepatol (2007) 1.71
Low circulating levels of dehydroepiandrosterone in histologically advanced nonalcoholic fatty liver disease. Hepatology (2008) 1.70
Biliary tract complications after orthotopic liver transplantation with choledochocholedochostomy anastomosis: endoscopic findings and results of therapy. Gastrointest Endosc (2002) 1.70
Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans. Clin Pharmacol Ther (2002) 1.68
HFE C282Y mutations are associated with advanced hepatic fibrosis in Caucasians with nonalcoholic steatohepatitis. Hepatology (2007) 1.60
Hereditary hemochromatosis: time for targeted screening. Ann Intern Med (2008) 1.60
Mouse population-guided resequencing reveals that variants in CD44 contribute to acetaminophen-induced liver injury in humans. Genome Res (2009) 1.60
Child- and parent-targeted interventions: the Memphis GEMS pilot study. Ethn Dis (2003) 1.59
Reciprocal effects of micro-RNA-122 on expression of heme oxygenase-1 and hepatitis C virus genes in human hepatocytes. Gastroenterology (2007) 1.59
Variability in the upper limit of normal for serum alanine aminotransferase levels: a statewide study. Hepatology (2009) 1.59
Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events. Hepatology (2010) 1.58
The Study of the Effects of Diet on Metabolism and Nutrition (STEDMAN) weight loss project: Rationale and design. Contemp Clin Trials (2005) 1.57
Pathological aspects of lipid peroxidation. Free Radic Res (2010) 1.56
Lipid-lowering agents that cause drug-induced hepatotoxicity. Clin Liver Dis (2007) 1.56
Reliability of the Roussel Uclaf Causality Assessment Method for assessing causality in drug-induced liver injury. Hepatology (2008) 1.53
Serum vitamin D concentrations and unexplained elevation in ALT among US adults. Dig Dis Sci (2011) 1.52
Fulminant hepatic failure as the initial presentation of acute autoimmune hepatitis. Clin Gastroenterol Hepatol (2004) 1.48
Incidence and predictors of 30-day readmission among patients hospitalized for advanced liver disease. Clin Gastroenterol Hepatol (2010) 1.48
Pain, stiffness, and fatigue in juvenile polyarticular arthritis: contemporaneous stressful events and mood as predictors. Arthritis Rheum (2005) 1.46
Improvement in liver histology is associated with reduction in dyslipidemia in children with nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr (2015) 1.46
Langerhans' cell histiocytosis involving the pituitary, thyroid, lung, and liver. Endocr Pract (2002) 1.45
Relationship between unexplained elevations in alanine aminotransferase and serum leptin in U.S. adults: results from the Third National Health and Nutrition Examination Survey (NHANES III). J Clin Gastroenterol (2004) 1.43
The STEDMAN project: biophysical, biochemical and metabolic effects of a behavioral weight loss intervention during weight loss, maintenance, and regain. OMICS (2009) 1.43
Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals. Ann N Y Acad Sci (2013) 1.40
Evaluation of quality control procedures for 24-h dietary recalls: results from the Girls Health Enrichment Multisite Studies. Prev Med (2004) 1.39
MicroRNA-196 represses Bach1 protein and hepatitis C virus gene expression in human hepatoma cells expressing hepatitis C viral proteins. Hepatology (2010) 1.38
Drug-induced QT prolongation in cirrhotic patients with transjugular intrahepatic portosystemic shunt. J Clin Gastroenterol (2011) 1.38
Drug-induced liver injury associated with statins. Semin Liver Dis (2009) 1.36
Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5. Clin Pharmacol Ther (2005) 1.35